Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Coronary Artery Disease
and you are
between 18 and 75
years old
The phase for this study is not defined.
Show me locations

The purpose

The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.

Provided treatments

  • Device: Firesorb
  • Device: XIENCE
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02890160. The sponsor of the trial is Shanghai MicroPort Medical (Group) Co., Ltd. and it is looking for 610 volunteers for the current phase.
Official trial title:
A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-II